BriaCell Therapeutics (BCTX) said Tuesday that patient enrollment for its pivotal Phase 3 study of Bria-IMT in combination with an immune checkpoint inhibitor for metastatic breast cancer is on track for expected completion by mid-2025.
The trial aims to enroll up to 354 patients, randomized 1:1 to receive either the BriaCell regimen or physician's choice, with a subset of 50 patients receiving Bria-IMT monotherapy, the company said.
BriaCell Therapeutics shares rose more than 6% in recent trading.
Price: 0.95, Change: +0.06, Percent Change: +6.22
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments